FCM
ALNY icon

Fourpath Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fourpath Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Sell
665
-26
-4% -$7.84K 0.03% 226
2026
Q1 		$229K Buy
+691
New +$235K 0.03% 200
2025
Q4 		– Sell
-483
Closed -$220K – 229
2025
Q3 		$220K Buy
+483
New +$197K 0.03% 217

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fourpath Capital Management's ALNY Position: Q2 2026 in Review

Fourpath Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.8% in Q2 2026, selling an estimated $7.84K and leaving 665 shares worth $200K. The position accounts for 0.03% of the portfolio, ranked #226.

Fourpath Capital Management first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $229K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Fourpath Capital Management held 665 shares of Alnylam Pharmaceuticals worth $200K as of Q2 2026.
  • Fourpath Capital Management sold 26 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.84K.
  • Alnylam Pharmaceuticals made up 0.03% of Fourpath Capital Management's portfolio in Q2 2026, its #226 holding.
  • Fourpath Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Fourpath Capital Management's Alnylam Pharmaceuticals position peaked at $229K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fourpath Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.